Grant: CIHR Fellowship
Direct Payment
$100,000.00
Is Insulin Resistance Related to Beta-amyloid and Hippocampal Atrophy Independent of Obesity and Diabetes Mellitus
EF 2017-18
Résumé
Alzheimer's disease (AD) affects roughly 46.8 million people worldwide and its prevalence will triple over the next 40 years. A pathological state known as insulin resistance (IR), in which cells fail to respond to a hormone called insulin, may be the biological mechanism of elevated AD biomarkers, thus increasing the risk of developing AD. IR increases the development of toxic protein clumps called beta-amyloid (Ab) and shrinkage in a brain region called hippocampus. Ab and hippocampal shrinkage are two prominent biomarkers in the brains of AD patients. However, the problem is that IR is commonly seen in other medical conditions like diabetes and obesity; therefore, these two conditions may mask the association between increased AD biomarkers and IR. However, no study has looked at the relationship between IR and AD biomarkers independent of diabetes and obesity. Levels of Ab and hippocampal shrinkage can be measured using brain imaging techniques called Positron Emission Tomography, which uses radioactive dyes that bind to Abeta, and Magnetic Resonance Imaging, respectively. The primary aim of this study is to see the association between IR severity and the level of Ab and hippocampal shrinkage in the following groups: obese AD, non-obese AD, obese cognitively normal adults (CN), and non-obese CN. Another objective of the study is to see whether IR is a predictor of levels of Ab and hippocampal shrinkage, after adjusting for presence of diabetes and obesity. This proposed study will help clarify whether IR promotes AD pathological burden independent of obesity and diabetes. Understanding the true relationship between IR and elevated AD biomarkers in CN will also provide a novel insight on the current understanding of the complex link between IR and increased risk of AD. Lastly, findings from this study will assist with the implementation of prevention strategies of AD, leading to novel therapeutic approaches and better treatment outcomes.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
New York, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
376855
Name
Chung Jun Ku
Region
New York
Country
United States of America
Orgtype
Research Institution
Instname2
Aging
Theme2
Clinical
Prcname2
Fellowships - Post-PhD
Projecttitle
Is Insulin Resistance Related to Beta-amyloid and Hippocampal Atrophy Independent of Obesity and Diabetes Mellitus
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Aging; Alzheimer'S Disease; Beta-Amyloid; Dementia; Diabetes Mellitus; Hippocampus; Insulin Resistance; Magnetic Resonance Imaging; Obesity; Positron Emission Tomography
Abstract
Alzheimer's disease (AD) affects roughly 46.8 million people worldwide and its prevalence will triple over the next 40 years. A pathological state known as insulin resistance (IR), in which cells fail to respond to a hormone called insulin, may be the biological mechanism of elevated AD biomarkers, thus increasing the risk of developing AD. IR increases the development of toxic protein clumps called beta-amyloid (Ab) and shrinkage in a brain region called hippocampus. Ab and hippocampal shrinkage are two prominent biomarkers in the brains of AD patients. However, the problem is that IR is commonly seen in other medical conditions like diabetes and obesity; therefore, these two conditions may mask the association between increased AD biomarkers and IR. However, no study has looked at the relationship between IR and AD biomarkers independent of diabetes and obesity. Levels of Ab and hippocampal shrinkage can be measured using brain imaging techniques called Positron Emission Tomography, which uses radioactive dyes that bind to Abeta, and Magnetic Resonance Imaging, respectively. The primary aim of this study is to see the association between IR severity and the level of Ab and hippocampal shrinkage in the following groups: obese AD, non-obese AD, obese cognitively normal adults (CN), and non-obese CN. Another objective of the study is to see whether IR is a predictor of levels of Ab and hippocampal shrinkage, after adjusting for presence of diabetes and obesity. This proposed study will help clarify whether IR promotes AD pathological burden independent of obesity and diabetes. Understanding the true relationship between IR and elevated AD biomarkers in CN will also provide a novel insight on the current understanding of the complex link between IR and increased risk of AD. Lastly, findings from this study will assist with the implementation of prevention strategies of AD, leading to novel therapeutic approaches and better treatment outcomes.
Competitiondate
201711
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Chung, Jun Ku
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $100,000~ $0~